Victory Capital Management Inc. Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. grew its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 677.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 237,250 shares of the biotechnology company’s stock after acquiring an additional 206,750 shares during the period. Victory Capital Management Inc.’s holdings in AnaptysBio were worth $7,948,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the 3rd quarter worth approximately $49,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC increased its position in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period. Finally, Duncan Williams Asset Management LLC purchased a new stake in AnaptysBio during the 3rd quarter worth $282,000.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $21.24 on Friday. The firm’s 50 day moving average price is $30.12 and its two-hundred day moving average price is $29.77. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $41.31. The stock has a market cap of $646.42 million, a price-to-earnings ratio of -3.49 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, research analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. HC Wainwright dropped their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Guggenheim raised their price target on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $54.64.

Insider Activity at AnaptysBio

In other news, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now directly owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. This trade represents a 55.40 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.